Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.

ABSTRACT: Successful drug delivery and overcoming drug resistance are the primary clinical challenges for management and treatment of cancer. The ability to rapidly screen drugs and delivery systems within physiologically relevant environments is critically important; yet is currently limited due to lack of appropriate tumor models. To address this problem, we developed the Tumor-microenvironment-on-chip (T-MOC), a new microfluidic tumor model simulating the interstitial flow, plasma clearance, and transport of the drug within the tumor. We demonstrated T-MOC's capabilities by assessing the delivery and efficacy of doxorubicin in small molecular form versus hyaluronic acid nanoparticle (NP) formulation in MCF-7 and MDA-MB-231, two cell lines representative of different molecular subtypes of breast c

SUBMITTER: Ozcelikkale A 

PROVIDER: S-EPMC5723544 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature